Tamoxifen exerts anti-peritoneal fibrosis effects by inhibiting H19-activated VEGFA transcription

BACKGROUND: Peritoneal dialysis (PD) remains limited due to dialysis failure caused by peritoneal fibrosis. Tamoxifen (TAM), an inhibitor of estrogen receptor 1 (ESR1), has been reported to treat fibrosis, but the underlying mechanism remains unknown. In this study, we sought to explore whether tamo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tingting, Sun, Zhengyu, Lai, Xueli, Lu, Hongtao, Liu, Lulu, Li, Shuangxi, Yuan, Ji-hang, Guo, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494369/
https://www.ncbi.nlm.nih.gov/pubmed/37697303
http://dx.doi.org/10.1186/s12967-023-04470-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494369/
https://www.ncbi.nlm.nih.gov/pubmed/37697303
http://dx.doi.org/10.1186/s12967-023-04470-3

Ejemplares similares